Homburger advised Siegfried Holding AG in connection with the bridge financing for the acquisition of three drug substances sites in the US and Australia
On May 1, 2026, Siegfried Holding AG, a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, closed the acquisition of three drug substances sites in the US and Australia from an affiliate of SK Capital Partners.
Homburger advised HWP Group on the acquisition of Global Market Access Solutions
On February 23, 2026, Health & Wellness Partners (HWP Group), a leading medical communications and strategic partner to the life sciences industry, has announced the acquisition of Global Market Access Solutions (GMAS), a market access and health economics consultancy with global operations.
Homburger advises AECOM on its acquisition of Consigli
March 23 2026 AECOM acquired Consigli, a leading Norwegian AI company transforming engineering and early-stage project design.
Homburger advises Mondelēz on its issuance of CHF 850 m in three-tranche CHF Offering
On April 10, 2026, Mondelēz International, Inc., successfully placed bonds in Switzerland in the aggregate amount of CHF 850 m. The CHF offering was comprised of CHF 325 m aggregate principal amount of 0.9575% senior notes due 2029, CHF 245 m aggregate principal amount of 1.2713% senior notes due 2032 and CHF 280 m aggregate …
Homburger advised Novartis AG on its USD 12 bn acquisition of Avidity Biosciences, Inc.
On March 2, 2026, Novartis AG (SIX: NOVN / NYSE: NVS), acting through one of its wholly-owned indirect subsidiaries,
Homburger advised EQT on the sale of ca. 14.3% of Galderma’s share capital via an accelerated bookbuilding process exiting in full their investment
On March 10, 2026, a consortium led by EQT, consisting of Sunshine SwissCo GmbH, the Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte. Ltd. (all acting as the Sellers), announced the launch of an accelerated
Homburger advised Roche Holding in the refinancing of its USD 7.5 bn revolving credit facility
On March 6, 2026, Roche Holding AG, Roche Holdings, Inc. and Roche Finanz AG entered into a Swiss law governed USD 7.5 bn revolving credit facility agreement arranged by and syndicated among twelve international banks, coordinated by Deutsche Bank.
Homburger advised Element Solutions on the acquisition of Micromax from Celanese
On February 2, 2026, Element Solutions Inc (NYSE: ESI), a global and diversified specialty chemicals technology company, announced that it has completed its previously announced acquisition of Micromax from Celanese Corporation (NYSE: CE) for approximately USD 500 m in cash.
Homburger advised ADC Therapeutics on the amendment of the financing agreement with HealthCare Royalty
On February 23, 2026, ADC Therapeutics SA (NYSE: ADCT) announced that it had amended its royalty purchase agreement with entities managed by HealthCare Royalty.
Homburger advised Raiffeisen Schweiz Genossenschaft on issuance of CHF 465 m State Treasury Notes by the State of North Rhine-Westphalia under its Debt Issuance Programme
On February 18, 2026, the State of North Rhine-Westphalia successfully completed its issuance of (i) CHF 100 m in aggregate principal amount of 0.3675 per cent.